TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01052623
Drug: Somatropin, Clonidine, L-Arginin-Hydrochloride, Estradiol valerate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg Estradiol valerate with for two days before GH-testing pre pubertal girls older than 8 years and pre pubertal boys older than 10 years. L-Arginin-Hydrochloride in the vein (0.5 g/kg KG maximum dose 30g) over 30 minutes. Clonidine orally (0,075 mg/m2 BSA). Somatropin-NutropinAq subcutaneum,a single one shot (dose 0.03 mg/KG, daily, over five days).
Study: NCT00700050
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be asked to expectorate sputum samples. If necessary to achieve this, subjects will inhale wet-nebulized 3% saline for up to 7 minutes each for up to 3 cycles.
Study: NCT00005908
Drug: Doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60 mg/m\^2 will be administered as a slow intravenous push on day 1
Study: NCT00005908
Drug: Capecitabine - Dose B
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dose B - Cohort 2 capecitabine 937.5 mg/m\^2 orally twice daily day 2-15
Study: NCT00005908
Drug: Capecitabine - Dose A
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: capecitabine 1000 mg/m\^2 orally twice daily day 2-15 for 4 cycles
Study: NCT03704506
Drug: Reyanning mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reyanning mixture , 20ml by mouth , 3 times per day for 7 days
Study: NCT03704506
Drug: Reyanning mixture simulator
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reyanning mixture simulator , 20ml by mouth , 3 times per day for 7 days
Study: NCT03704506
Drug: amoxil capsule simulator
Normalized name: Amoxi Drop
Approvals — FDA: no, EMA: no, PMDA: no
Description: amoxil capsule simulator , 0.5g by mouth , 3 times per day for 7 days
Study: NCT03532776
Drug: Condylox Topical Gel 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apply twice daily for three consecutive days, then discontinuing for four consecutive days, up to four treatment cycles
Study: NCT03029845
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will take placebo twice a day for 2 weeks
Study: NCT00511654
Drug: GW823296 tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: GW823296 immediate release tablets will be available as white film-coated tablets containing 5 milligrams (mg) and 20 mg of GW823296 for oral administration.
Study: NCT01306409
Drug: cera, darbepoetin, epoetin-beta
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epoetin once/ 2wk, cera once/ month, darbepoetin once/ 2wk
Study: NCT00511654
Drug: GW823296 matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablets will be identical in appearance to the GW823296 tablets.
Study: NCT02970721
Drug: Antipsychotic
Normalized name: ANTIPSYCHOTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic monotherapy
Study: NCT02970721
Drug: Antidepressant
Normalized name: Antidepressant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant monotherapy
Study: NCT02956876
Drug: standard chemotherapy for colorectal cancer
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard chemotherapy for colorectal cancer
Study: NCT01980745
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05631782
Drug: Shenkang decoction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given Shenkang decoction on the basis of the above treatment. Shenkang decoction prescription: 15 g of semen cuscutae, herba epimedii and pericarpium arecae. 20 g of Eucommia ulmoides Oliv., radix astragali, codonopsis pilosula, salvia miltiorrhiza, tuckahoe, atractylodes macrocephala, Chinese yam, honeysuckle, polyporus umbellatus and dandelion. 15 g of safflower. 12 g of processed Fuzi. 10 g of Radix phytolaccae and sage. Golden cherry son 20 g and puzzle kernel 15 g were added to patients with frequent proteinuria and nocturia took. Yellow cypress 15 g was added to patients with damp-heat in lower-Jiao. The decoction pieces were purchased from the Traditional Chinese Medicine and Pharmacy Department of the First People's Hospital of Zunyi City. They were decocted by computer automatic decocting machine (model) and divided into 150 mL / bag, taken orally, once in the morning, noon and evening, 3 times / day, 1 bag / time, one pair a day. Treatment lasted for 10 - 14 days.
Study: NCT02218671
Drug: WE 941 OD tablets
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01776840
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 capsules administered orally once daily continuously starting on Day 1, Cycle 1 until disease progression, or unacceptable toxicity, or the final analysis of progression-free survival
Study: NCT03532776
Drug: Placebo Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apply twice daily for three consecutive days, then discontinuing for four consecutive days, up to four treatment cycles
Study: NCT01171885
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml of 0.9% saline
Study: NCT00607789
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: identical to study drug
Study: NCT02488070
Drug: Gallium Ga 68-labeled PSMA Ligand Glu-urea-Lys(Ahx)
Normalized name: Gallium Ga 68-labeled psma ligand Glu-urea-Lys(ahx)-hbed-CC
DrugBank: Gallium Ga-68 gozetotide (DB16019)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenously-administered (IV) radioisotope
Study: NCT04492787
Drug: Changkang Placebo Granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take Changkang Placebo granule before meals twice a day , one bag for each time
Study: NCT04387916
Drug: KC1036
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 1: Dose-escalation phase , KC1036 10mg\~80mg, consists of 5 Cohorts. Part 2: Dose-expansion phase, consists of 3\~4 Cohorts based on part 1. Part 3:RP2D-extension phase, Recommended dose of KC1036 based on part 1and part 2.
Study: NCT03120949
Drug: Concomitant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate 15 to 25 mg/week (or ≥ 10 mg/week if there was documented intolerance to higher doses). (Subject maintained their stable dose and route (oral, SC, or IM) during the core study and for ≥ 12 additional weeks of OLE.)~Folic acid ≥ 5 mg per week or equivalent
Study: NCT04593771
Drug: BCG-PPD
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG-PPD was used for skin test in 40 healthy people, and BCG-PPD was marketed in other 40 healthy people (as control)
Study: NCT00515281
Drug: inhaled nitric oxide
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: The amount of gas will be carefully controlled and adjusted to the level that best improves the function of subject's lungs. The subject will remain on inhaled nitric oxide until he/she reaches 33 weeks of gestation if assigned to the treatment arm, or until the 8th day of the study if he/she is assigned to the control arm.
Study: NCT02536781
Drug: Anthocyanin
Normalized name: Anthocyanin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-inflammation gel
Study: NCT02536781
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blank gel
Study: NCT02971683
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of Abatacept subcutaneous
Study: NCT00303017
Drug: Naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: non-steroidal anti-inflammatory drug
Study: NCT00621517
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 capsule nightly for six weeks
Study: NCT03469999
Drug: Dysport Injectable Product
Normalized name: Dysport Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selected dose of medication will be determined by affected muscle(s), severity of spasticity, and the patient's body weight. We will follow the recommended total Dysport dose of 10-15 units/kg per limb, not to exceed 15 units/kg for unilateral lower limb, 30 units/kg for bilateral lower limb, or a total of 1000 units, whichever is lower in a given session.
Study: NCT00739024
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet, oral, once daily
Study: NCT02249013
Drug: Adjuvant Chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic chemotherapy included the standard combination of carboplatin (AUC 6) and paclitaxel (175 mg/m2) administered every 21 days as neoadjuvant (2-4 cycles) plus adjuvant regimens (2-4 cycles), in the total of 6 cycles of systemic chemotherapy.
Study: NCT02838589
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of subcutaneous injection of 20 μL isotonic saline (placebo).
Study: NCT02791438
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-matching azilsartan granules and tablets
Study: NCT04746365
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatments
Study: NCT02839876
Drug: Intravenous acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subject receives 1 g acetaminophen by the intravenous route every 6 hours for 4 doses beginning in the preoperative holding area.
Study: NCT02839876
Drug: Oral acetaminophen
Normalized name: acetaminophen Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subject receives 1 g acetaminophen by the oral route every 6 hours for 4 doses beginning in the preoperative holding area.
Study: NCT01438372
Drug: Intravenous iron sucrose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron sucrose will be administered on days 1, 7, 14, and 21 using the formula: Total dose: (normal Hb for age - initial Hb)/100 x blood volume (ml) x 3.4 x 1.5. First dose will be infused over 30 minutes, with subsequent doses administered over 15 minutes if no reactions encountered.
Study: NCT03383692
Drug: DS-8201a
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: DS-8201a is provided as a sterile lyophilized powder of DS-8201a in a glass vial, which will be dissolved and administered as an intravenous (IV) solution
Study: NCT00511459
Drug: AMG 386 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 386 Placebo \[blinded\]
Study: NCT02414802
Drug: low-molecular-weight heparin calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: anticoagulation therapy will be administered via subcutaneous injection of low-molecular-weight heparin calcium (LMWH-Ca 5,000 U/12 h) in both arms at discharge
Study: NCT04453306
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: innocuous substance is coated in tablets in an independent laboratory
Study: NCT00660764
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral
Study: NCT03528564
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline to be administered to half of study participants (equal volume to Eprex x 1-2 subcutaneous injections)
Study: NCT03201393
Drug: Low-dose naltrexone and acetaminophen combination
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Twice a day
Study: NCT03201393
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice a day
Study: NCT00384371
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00586898
Drug: Testosterone transdermal gel
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: an androgenic anabolic steroid
Study: NCT01774929
Drug: TTS-fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: TTS-fentanyl patches releasing at the rate of 12.5 microgram per hour for 3 days. The patches will be replaced every 3 days until 30 days.
Study: NCT01748851
Drug: XELOX
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: capecitabine 1000mg/m2 bid po D1-D14
Study: NCT01748851
Drug: FOLFOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-FU 400mg/m2 iv push D1, 5-FU 1200mg/m2 over 22hr D1,D2
Study: NCT00386802
Drug: Antifungal drug. VORICONAZOL. (VFEND®)
Approvals — FDA: no, EMA: no, PMDA: no
Description: I.V charge dose 6 mg/kg/12h (2 doses) Maintenance iv treatment 4 mg/kg/12h during 6 days, followed by oral treatment (200 mg/12h)
Study: NCT00471549
Drug: Statin (simvastatin)
Normalized name: Nystatin
DrugBank: Nystatin (DB00646)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01969084
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01332318
Drug: XP13512
Approvals — FDA: no, EMA: no, PMDA: no
Description: XP13512 once daily for 16 days
Study: NCT01332318
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: XP13512 placebo once daily for 16 days
Study: NCT01361789
Drug: parecoxib, valdecoxib, etoricoxib
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg parecoxib (Dynastat, Pfizer®) one hour before surgery and 40 mg valdecoxib (prodrug of parecoxib, Bextra, Pfizer®)were given 8 hour after surgery.~After retraction of parecoxib from the market:~Etoricoxib (Arcoxia, MSD) 120 mg given one hour before surgery
Study: NCT01361789
Drug: parecoxib, valdecoxib, parecoxib and dexamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: combination of both drugs
Study: NCT00579475
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00525200
Drug: 5-Fluoruracil, Cisplatinum
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 FU 1000mg/m2; days 1-5; 3 cycles: q21~Cisplatin 80mg/m2; day 1; 3 cycles: q21
Study: NCT01958047
Drug: ASP3652
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT04475016
Drug: Triprilimab
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240 mg IV on Day 1
Study: NCT02901301
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000mg/m2, PO, BID, Day 1-14
Study: NCT03721900
Drug: SHX-001 Active low dose
Normalized name: eptacog alfa activated 0.001 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ketamine transdermal patch
Study: NCT03721900
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: transdermal patch
Study: NCT03721900
Drug: SHX-001 Active High dose
Normalized name: eptacog alfa activated 0.001 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ketamine transdermal patch
Study: NCT01350388
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 placebo tablet per day for 24 weeks
Study: NCT03904368
Drug: Gonadotropins
Normalized name: GONADOTROPINS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gonadotropin stimulation of follicular growth
Study: NCT02770768
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Observational study using electroencephalogram (EEG) and eye movement tracking device at baseline, week 4, and week 8 while subjects are taking either Flibanserin or matching placebo.
Study: NCT04312594
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients were administered Placebo taken orally as tablets twice daily
Study: NCT04357587
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 825 mg/m2 orally twice a day on days where radiation therapy is given
Study: NCT00928876
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo s/c daily for four weeks
Study: NCT00860522
Drug: JVRS-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Level 1: 0.5 µg/Kg D1,8,15; Level 2: 1.0 µg/Kg D1,8,15; Level 3:2.0 µg/Kg 1,15; Level 4: 2.0 µg/Kg D1,8,15; Level 5: 4.0 µg/Kg D1,15
Study: NCT00860522
Drug: JVRS-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Change to Stage 2 with starting dose of 4.0 µg/Kg D1,8,15 if no toxicity level by Level 5.
Study: NCT03669484
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Solution for intravenous administration, 50 mg/mL. Used for anesthesia induction (at a dose of 2 mg/kg) and, if necessary, anesthesia maintenance (the dose was selected individually)
Study: NCT02338310
Drug: Aromatase Inhibitors
Normalized name: Aromatase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Choice of AI is according to centre policy; any brand can be used
Study: NCT03392779
Drug: ZSP1601 25 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZSP1601 tablet administered orally once daily under fasted condition
Study: NCT03392779
Drug: Placebo 175 mg
Normalized name: Ascorbic Acid/Cyanocobalamin/Docusate Sodium/Folic Acid/Iron/Succinic Acid/Zinc;Placebo 175 MG-12 MCG-50 MG-1 MG-75 MG-150 MG-10 MG; NA Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo matching to ZSP1601 orally once daily under fasted condition
Study: NCT02685072
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNP + Placebo
Study: NCT03392779
Drug: Placebo 275 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo matching to ZSP1601 orally once daily in the fasting state
Study: NCT03392779
Drug: ZSP1601 350 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZSP1601 tablets administered orally once daily under fasted condition
Study: NCT03903367
Drug: Fentanyl Citrate
Normalized name: Fentanyl Citrate
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: standard GA and receive fentanyl infusion 2 mcg/kg/h after tracheal intubation and stopped at the end of the operation ,When HR or MBP increased ≥20% from base line readings, incremental dose of fentanyl will be given (2mcg /kg).
Study: NCT03392779
Drug: Placebo 350mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo matching to ZSP1601 orally once daily under fasted condition
Study: NCT03392779
Drug: Placebo 100mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo matching to ZSP1601 orally once daily under fasted or fed condition
Study: NCT01210352
Drug: oxymorphone HCl
Normalized name: oxymorphone HCl
DrugBank: Oxymorphone (DB01192)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Comparison of different dosages of drug, 0.05mg/kg, 0.10mg/kg, 0.15mg/kg or 0.20mg/kg oral liquid oxymorphone
Study: NCT01689233
Drug: TRx0237 200 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRx0237 100 mg tablets will be administered twice daily.
Study: NCT01689233
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets will be administered twice daily. The active placebo tablets include 4 mg of TRx0237 as a urinary and fecal colorant to maintain blinding; hence the placebo group will receive a total of 8 mg/day of TRx0237.
Study: NCT03392779
Drug: ZSP1601 50 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZSP1601 tablets administered orally once daily under fasted or fed condition due to the results of Cohort FE for 14 Days(a total of 14 doses).
Study: NCT01442727
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: dicalcium phosphate capsule matching the selenium capsule in appearance; consumed once daily with breakfast
Study: NCT00681265
Drug: polyethylene glycol 400/propylene glycol
Normalized name: POLYETHYLENE GLYCOL 400/PROPYLENE GLYCOL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eye drop with the active agents polyethylene glycol 400 0.4% /propylene glycol 0.3%, topical ophthalmic formulation, single instillation
Study: NCT02717442
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intratympanic injection of placebo
Study: NCT03412006
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablets are given twice daily over a treatment period of 6 months
Study: NCT03392779
Drug: Placebo 50 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo matching to ZSP1601 orally once daily under fasted or fed condition due to the results of Cohort FE for 14 Days(a total of 14 doses).
Study: NCT00382109
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00382109
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03392779
Drug: ZSP1601 100 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZSP1601 tablets administered orally once daily under fasted or fed condition due to the results of Cohort FE for 14 Days(a total of 14 doses).
Study: NCT03392779
Drug: Placebo 100 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo matching to ZSP1601 orally once daily under fasted or fed condition due to the results of Cohort FE for 14 Days(a total of 14 doses).
Study: NCT01780584
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of different dosages of drug. In low dose group, placebo was given alternately with oral T3 every 12h with a total 3 doses for placebo and 3 doses for oral T3
Study: NCT01780584
Drug: Oral T3 high dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of different dosages of drugs. Oral T3 high dose is 0.5 mcg/kg q12h
Study: NCT01039805
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo
Study: NCT01039805
Drug: GSK962040 (75 mg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort 2 = 75 mg
Study: NCT01126177
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (excipients of the SNG001 solution only)
Study: NCT04401280
Drug: CPP-ACP
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: applied in accordance with the manufacturer's specifications
Study: NCT01464671
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anticoagulation during percutaneous coronary intervention
Study: NCT01187264
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: once weekly for a total duration of 12 weeks or earlier till patient achieves PASI 75
Study: NCT00332631
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04174365
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally daily for up to Week 8.